<DOC>
	<DOC>NCT00786643</DOC>
	<brief_summary>The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.</brief_summary>
	<brief_title>Study of Gamma Interfereon in Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Metastatic colorectal cancer, histologically or cytologically confirmed Age 18 or greater Adequate hematologic function (ANC &gt; 1500, hemoglobin &gt; 10 g/dl, platelet count &gt; 100,000) Adequate hepatic parameters (bilirubin &lt; 2.0, Alk. Phos &lt; 5 times normal, ALT &lt; 5 times normal) Adequate renal function (creatinine &lt; 2.0) Performance status ECOG 02 02 prior lines of chemotherapy for metastatic colorectal cancer are allowed. Prior 5FU/LV or capecitabine allowed either in the adjuvant setting, or in the metastatic setting or both. Absence of other serious concurrent medical illnesses Evaluable or measurable disease for phase I; measurable disease only for phase II Histologies other than adenocarcinoma Previous grade 4 toxicity to 5FU +/ LV or capecitabine Uncontrolled brain metastases Chronic diarrhea (greater than five bowel movements per day) Previous chemotherapy or radiation therapy less than 4 weeks prior to study day 1 (less than 6 weeks for chemotherapy with Mitomycin or nitrosoureas) Major surgery within 2 weeks before study entry Known allergic sensitivity to leucovorin Prior exposure to IFNÎ³ Previous hematopoietic growth factor (e.g. epoetin alfa or darbepoietin less than 2 weeks prior to study day 1) Pregnancy or breast feeding. Women of childbearing potential must have a negative pregnancy test before the first dose. Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ Inability to provide written and informed consent Uncontrolled hypertension History of deep venous thrombosis or CVA Prior exposure to bevacizumab Proteinuria &gt; 500 mg/24 hr</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Gamma Interferon</keyword>
	<keyword>5-FU</keyword>
	<keyword>LV</keyword>
</DOC>